theme07のラベル

Our mission is to effectively utilize innovative formulation technologies for promoting drug discovery research. We also use these technologies to create new pharmaceutical agents with higher added values.

We look forward to collaborating with you.

Pharmaceuticals Research Center
Laboratory for Chemistry, Manufacturing and Control

theme07のメイン画像

Creating for Tomorrow


“ Pharmaceutical Technologies ”

Message 

CMC研究部 主幹研究員 画像

Kazunobu Konishi, PhD

Principal Scientist
Laboratory for Chemistry, Manufacturing and Control

We are responsible for the following research activities at the early stages of drug development: Formulation design, process development, physical property evaluation, production of investigational drugs, and development of new formulation technologies. We have thus far produced peptide- and protein-based drugs (such as Teribone® and Recomodulin®) as lyophilized formulations that need to be reconstituted prior to administration. In recent years, we have also been working on the synthesis of new non-standard peptides.

We are particularly concerned about the considerable burdens placed on patients and healthcare professionals by the use of peptide and protein formulations for injection. These burdens include pain at administration, increased frequency of hospital visits, reconstitution procedures, and specific requirements for storage. To address these problems, we are seeking novel formulation technologies that can alleviate these burdens as much as possible.

Recruitment theme 

7.1 Novel techniques for stabilizing peptide- and protein-based drugs in aqueous solutions

Applications proposing to use the following approaches will not be considered:

  • Lyophilization
  • Any procedures that prevent the subcutaneous injection of the drugs
  • Covalent modification of the drugs
7.2 New technologies for the sustained release of peptides and proteins
  • Proposals should ideally include in vivo data.
  • Proposed technologies must meet the following three requirements:
a )
Controlled release has been shown to continue for at least four weeks.
b )
Proposed methods should be clearly superior to existing techniques.
c )
Proposed methods should be compatible with subcutaneous administration.

Subscription 

Click “Apply” to proceed to the application form.

pagetopボタン